FOXM1 and cancer: These findings reveal that WDR5 loss cannot be used to model the effects of WIN site inhibitors on cancer cells, show how an essential protein can be partially inhibited to induce a pro-therapeutic response, and support distinct applications of WIN site inhibitors and WDR5 degraders in the clinic.